Search results for "Prostate Cancer"

showing 10 items of 413 documents

Pentafecta Rates of Three-Dimensional Laparoscopic Radical Prostatectomy: Our Experience after 150 Cases

2017

Introduction Three-dimensional (3D) laparoscopy with a flexible camera was developed to overcome the main limitation of traditional laparoscopic surgery, which is two-dimensional (2D) vision. The aim of our article is to present the largest casistic of 3D laparoscopic radical prostatectomy (LRP) available in literature and evaluate our results in terms of pentafecta and compare it with the literature. Methods We retrospectively evaluated consecutive patients who underwent LRP with 3D technology between March 2014 and December 2015. Total operative time (TOT), anasthomosis time (AT), blood loss and complications were registered. All patients presented at least 3 months of follow-up. Surgical…

MaleLaparoscopic surgeryPentafectamedicine.medical_specialtyLaparoscopic radical prostatectomymedicine.medical_treatment030232 urology & nephrologyMEDLINE03 medical and health sciencesProstate cancerImaging Three-Dimensional0302 clinical medicinemedicineHumansLaparoscopyAgedRetrospective StudiesProstatectomyProstate cancermedicine.diagnostic_testbusiness.industryProstatectomyLaparoscopic radical prostatectomyProstatic NeoplasmsRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryLaparoscopy Laparoscopic radical prostatectomy Pentafecta Prostate cancer Three-dimensional laparoscopyPatient Outcome AssessmentSurgery Computer-Assisted030220 oncology & carcinogenesisLaparoscopybusinessThree-dimensional laparoscopyUrologia Journal
researchProduct

Editorial comment on: Measurement of serum isoform [–2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of p…

2017

MaleNephrologyGene isoformPathologymedicine.medical_specialtyUrology030232 urology & nephrology03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicinemedicineHumansProtein IsoformsIn patientmedicine.diagnostic_testbusiness.industryProstatic NeoplasmsMagnetic resonance imagingProstate-Specific Antigenmedicine.diseaseMagnetic Resonance ImagingProstate-specific antigenNephrology030220 oncology & carcinogenesisbusinessScandinavian Journal of Urology
researchProduct

Kinetics of serum total and free prostate-specific antigen (PSA) after extended multisite prostate biopsy: Comparison among biopsy, transurethral res…

2008

Abstract Background The kinetics and reproducibility of serum prostate-specific antigen (PSA) following extended multisite biopsies are unknown. The aim of this study was to examine the kinetics of hematogenous leakage of PSA molecules by comparing the postintervention PSA manner among extended biopsies, transurethral resection of the prostate (TURP) and biopsy plus TURP. Methods Total and free PSA values were examined before and sequentially after intervention (at 1 hour, 24 hours, 2 days, 14 days, and 28 days), in patients who underwent 14-core prostate biopsy (Biopsy, n = 53), TURP (TURP, n = 21), or prostate biopsy plus TURP (Biopsy+TURP, n = 18). Results Ten patients in the Biopsy grou…

MaleNephrologymedicine.medical_specialtyProstate biopsyBiopsyUrologymedicine.medical_treatmentUrologyurologic and male genital diseasesProstate cancerProstateInternal medicineBiopsymedicineHumansProspective StudiesAgedTransurethral resection of the prostateAged 80 and overmedicine.diagnostic_testGenitourinary systembusiness.industryProstateTransurethral Resection of ProstateProstatic NeoplasmsMiddle AgedProstate-Specific Antigenmedicine.diseaseSurgeryProstate-specific antigenmedicine.anatomical_structureOncologybusinessUrologic Oncology: Seminars and Original Investigations
researchProduct

How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participat…

2020

Purpose Therapeutic strategies for prostate cancer (PCa) have been evolving dramatically worldwide. The current article reports on the evolution of surgical management strategies for PCa in Italy. Methods The data from two independent Italian multicenter projects, the MIRROR-SIU/LUNA (started in 2007, holding data of 890 patients) and the Pros-IT-CNR project (started in 2014, with data of 692 patients), were compared. Differences in patients' characteristics were evaluated. Multivariable logistic regression models were used to identify characteristics associated with robot-assisted (RA) procedure, nerve sparing (NS) approach, and lymph node dissection (LND). Results The two cohorts did not …

MaleNephrologymedicine.medical_specialtyTime FactorsUrologymedicine.medical_treatment030232 urology & nephrologyLymph node dissectionLogistic regression03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineLUNA studyBiopsyHumansMedicineProspective StudiesNerve sparingLymph nodeAgedProstatectomyProstate cancermedicine.diagnostic_testbusiness.industryProstatectomyMIRROR SIU/LUNA studyLymph node dissection MIRROR SIU/LUNA study Nerve sparing Pros-IT CNR study Prostate cancer Robotic proceduresProstatic NeoplasmsCancerPros-IT CNR studyMiddle Agedmedicine.diseaseMIRROR SIUDissectionRobotic proceduresLogistic Modelsmedicine.anatomical_structureItaly030220 oncology & carcinogenesisLymph node dissection; MIRROR SIU/LUNA study; Nerve sparing; Pros-IT CNR study; Prostate cancer; Robotic procedures; Aged; Humans; Italy; Logistic Models; Male; Middle Aged; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Time FactorsLymph node dissection; MIRROR SIU/LUNA study; Nerve sparing; Pros-IT CNR study; Prostate cancer; Robotic proceduresbusiness
researchProduct

Plasma hTERT mRNA discriminates between clinically localized and locally advanced disease and is a predictor of recurrence in prostate cancer patients

2012

Since the introduction of prostate-specific antigen (PSA) testing, new prostate cancer (PCa) patients are diagnosed earlier and most have localized and locally advanced disease. Current diagnosis methods lack specificity and sensitivity, leading to overdiagnosis and overtreatment of patients with low-risk organ-confined localized disease. Therefore, new non-invasive molecular tools are needed to discriminate between localized and locally advanced disease.Plasma telomerase reverse transcriptase (hTERT) mRNA levels were determined by qRT-PCR in 49 patients with localized and locally advanced PCa. Diagnostic accuracy and efficacy as a prognostic factor of biochemical recurrence of plasma hTERT…

MaleOncologyBiochemical recurrencemedicine.medical_specialtyPathologyTelomeraseClinical BiochemistryProstate cancerAntigenRecurrenceInternal medicineDrug DiscoveryBiomarkers TumormedicineHumansTelomerase reverse transcriptaseRNA MessengerOverdiagnosisTelomeraseAgedNeoplasm StagingPharmacologybusiness.industryProstatic NeoplasmsMiddle Agedmedicine.diseaseROC CurveArea Under CurveLocalized diseaseLocally advanced diseasebusinessExpert Opinion on Biological Therapy
researchProduct

Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers

2011

Abstract Mast cells (MC) are c-Kit–expressing cells, best known for their primary involvement in allergic reactions, but recently reappraised as important players in either cancer promotion or inhibition. Here, we assessed the role of MCs in prostate tumor development. In prostate tumors from both tumor-prone transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and human patients, MCs are specifically enriched and degranulated in areas of well-differentiated (WD) adenocarcinoma but not around poorly differentiated (PD) foci that coexist in the same tumors. We derived novel TRAMP tumor cell lines, representative of WD and PD variants, and through pharmacologic stabilization or geneti…

MaleOncologyCancer Researchmedicine.medical_specialtyEpithelial-Mesenchymal TransitionMice TransgenicAdenocarcinomaBiologymedicine.disease_causeCell DegranulationMiceProstate cancerProstateCell Line TumorInternal medicineTumor MicroenvironmentmedicineMast CellAnimalsHumansMast CellsReceptors Tumor Necrosis Factor Member 25Tumor microenvironmentAdenocarcinoma; Animals; Carcinoma Neuroendocrine; Cell Degranulation; Cell Line Tumor; Disease Progression; Epithelial-Mesenchymal Transition; Humans; Male; Mast Cells; Matrix Metalloproteinase 9; Mice; Mice Inbred C57BL; Mice Transgenic; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Receptors Tumor Necrosis Factor Member 25; Tumor Microenvironment; Cancer Research; OncologyAnimalProstatic NeoplasmsCancermedicine.diseasehumanitiesCarcinoma NeuroendocrineMice Inbred C57BLProto-Oncogene Proteins c-kitmedicine.anatomical_structureMatrix Metalloproteinase 9OncologyTumor progressionProstatic NeoplasmDisease ProgressionAdenocarcinomaCarcinogenesisHumanTramp
researchProduct

A high cannabinoid CB1 receptor immunoreactivity is associated with disease severity and outcome in prostate cancer

2008

In the light of findings indicating that cannabinoids can affect the proliferation of a number of cancer cell types and that cannabinoid receptor expression is higher in prostate cancer cell lines than in non-malignant cells, we investigated whether the level of cannabinoid 1 receptor immunoreactivity (CB(1)IR) in prostate cancer tissues is associated with disease severity and outcome. Formalin-fixed paraffin-embedded non-malignant and tumour tissue samples from patients who were diagnosed with prostate cancer at a transurethral resection for voiding problems were used. CB(1)IR, which was scored in a total of 399 cases, was associated with the epithelial cell membranes, with little staining…

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyPrognostic variableCannabinoid receptormedicine.medical_treatmentAdenocarcinomaProstate cancerReceptor Cannabinoid CB1Internal medicineBiomarkers TumormedicineHumansSurvival rateAgedCell ProliferationProportional Hazards Modelsbusiness.industryProportional hazards modelCell MembraneProstatic NeoplasmsEpithelial Cellsmedicine.diseaseImmunohistochemistrySurvival RateOncologyArea Under CurveCancer cellImmunohistochemistryCannabinoidbusinessEuropean Journal of Cancer
researchProduct

Real-Time Quantification of Human Telomerase Reverse Transcriptase mRNA in the Plasma of Patients with Prostate Cancer

2006

The aim of this study was to evaluate the potential diagnostic value of quantitative analysis of human telomerase reverse transcriptase (hTERT) mRNA in plasma for noninvasive diagnosis of prostate cancer (PCa). Expression levels of hTERT were analyzed by real-time quantitative RT-PCR in 68 patients showing elevated prostate-specific antigen (PSA) levels and a control group of 44 healthy volunteers. Sensitivity and specificity were determined and compared to the corresponding PSA values. Median values for hTERT gene expression in the PCa patients (0.72 ng; range 0.01-12.86) were statistically significantly higher (P < 0.001) than in the control group (0.13 ng; 0.02-0.35). Patients with clini…

MaleOncologyPathologymedicine.medical_specialtyStatistics as TopicProstatitisGeneral Biochemistry Genetics and Molecular BiologyPlasmaProstate cancerHistory and Philosophy of ScienceAntigenProstateInternal medicinemedicineHumansTelomerase reverse transcriptaseRNA MessengerTelomeraseMessenger RNAReverse Transcriptase Polymerase Chain Reactionbusiness.industryGeneral NeuroscienceProstatic Neoplasmsmedicine.diseaseHtert mrnamedicine.anatomical_structurebusinessQuantitative analysis (chemistry)Annals of the New York Academy of Sciences
researchProduct

CCR5 Proinflammatory Allele in Prostate Cancer Risk

2009

Prostate cancer (PCa) is the most common malignant neoplasm in older men in Western countries. The number of affected older men is increasing. Therefore, strategies for prevention of prostate cancer are crucial. To this purpose it is essential to know the mechanisms involved in development and progression of this malignancy. Recently, an increasing body of genetic and epidemiological studies proposed new hypotheses for prostate carcinogenesis. It has been suggested that genetic factors as well as exposure to environmental factors such as infectious agents, dietary carcinogens, and hormonal imbalances participate in PCa development. Besides, chronic inflammation plays a key role in PCa. Taki…

MaleOncologyProstate Cancer Inflammation CCR5delta32 deletionmedicine.medical_specialtyReceptors CCR5Pilot ProjectsInflammationBiologyMalignancyGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineProstate cancerHistory and Philosophy of ScienceProstateInternal medicineMolecular geneticsEpidemiologymedicineHumansAlleleAllelesAgedSettore MED/04 - Patologia GeneraleAged 80 and overGeneral NeuroscienceProstatic Neoplasmsmedicine.diseasemedicine.anatomical_structureImmunologyInflammation Mediatorsmedicine.symptomAnnals of the New York Academy of Sciences
researchProduct

Antiandrogens alone or in combination for treatment of prostate cancer: The European experience

1989

Abstract In Europe, antiandrogens have been used for many years to treat prostate cancer, either as monotherapy or as part of a “combination therapy” with either surgical or chemical castration. However, considerable debate still exists regarding the relative benefits of combination therapy versus antiandrogen monotherapy or castration alone. This article reviews the European experience with antiandrogen therapy, including the personal experiences of the authors.

MaleOncologymedicine.medical_specialtyCombination therapyAntiandrogensmedicine.drug_classUrologyurologic and male genital diseasesAntiandrogenchemistry.chemical_compoundProstate cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineAntiandrogen TherapyChemical castrationRandomized Controlled Trials as TopicGynecologybusiness.industryProstatic NeoplasmsAndrogen Antagonistsmedicine.diseaseCombined Modality TherapyFlutamideEuropeCastrationchemistrybusinessOrchiectomyhormones hormone substitutes and hormone antagonistsUrology
researchProduct